Jasper Therapeutics stock gains 4.05 percent as vote nears

Published on 09/27/2026 at 06:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jasper Therapeutics stock stood at USD 0.61 on September 25, 2026, as a shareholder vote set a 1-for-15 to 1-for-35 split range. Q2 loss narrowed to USD 2.76 million.

JSPR, US47191J1060, Illustration mit AI erstellt.

Jasper Therapeutics stock (ISIN US47191J1060) was last at USD 0.61 on the Nasdaq Capital Market on September 25, 2026 at 4:00 p.m. ET, up 4.05 percent from USD 0.59. The immediate issue for shareholders is a September 30, 2026 vote on a possible reverse split and a larger authorized share pool.

Reverse split vote sets the agenda

According to StockTitan, Jasper will ask shareholders on September 30, 2026 to authorize a reverse stock split between 1-for-15 and 1-for-35. The board would retain discretion to select the ratio and implement it by December 31, 2026.

The same filing identifies a Nasdaq compliance deadline of November 30, 2026 after the company received notice that its bid price had stayed below the USD 1.00 minimum. The proxy cites a closing price of USD 0.6864 on September 3, 2026, giving the proposal a direct listing-compliance rationale.

Share authorization adds dilution risk

The second proposal would increase authorized common shares from 490.0 million to 675.0 million. Jasper says the additional capacity would support conversion of preferred shares issued in connection with the July 16, 2026 Kira Pharmaceuticals merger and related financing, while the authorization also gives the company more flexibility for future capital needs.

Financial pressure remains visible despite the recent share gain. RTT News reported that Jasper's Q2 2026 net loss narrowed to USD 2.76 million, or USD 0.10 per share, from USD 26.72 million, or USD 1.74 per share, in Q2 2025. Cash and cash equivalents totaled USD 7.3 million on June 30, 2026.

Jasper stock remains below Nasdaq threshold

Jasper's September 25, 2026 market capitalization was USD 9.9 million, with 163,087 shares traded. The 52-week range was USD 0.32 to USD 2.69, placing the latest price 77.32 percent below the yearly high.

For investors, the September 30 vote links the stock's listing status with its capital structure. The proposed split could lift the quoted per-share price, while the authorized-share increase preserves financing flexibility and keeps potential dilution in the calculation.